MARKET

BNXTF

BNXTF

BioNxt Solutions Inc
OTCMQB
0.227
NaN%
Closed 09:30 09/11 EDT
OPEN
--
PREV CLOSE
0.227
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.340
52 WEEK LOW
0.198
MARKET CAP
30.88M
P/E (TTM)
-4.3635
1D
5D
1M
3M
1Y
5Y
1D
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
Barchart · 5d ago
Weekly Report: what happened at BNXTF last week (0831-0904)?
Weekly Report · 5d ago
Weekly Report: what happened at BNXTF last week (0824-0828)?
Weekly Report · 08/31 09:04
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
Barchart · 08/26 02:05
Weekly Report: what happened at BNXTF last week (0817-0821)?
Weekly Report · 08/24 09:04
BioNxt Extends Convertible Debentures and Issues 16.9 Million Warrants
TipRanks · 08/22 00:04
BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Barchart · 08/21 17:30
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
Barchart · 08/19 02:05
More
About BNXTF
BioNxt Solutions Inc. is a Canada-based bioscience company. The Company focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).

Webull offers BioNxt Solutions Inc stock information, including OTCMQB: BNXTF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNXTF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BNXTF stock methods without spending real money on the virtual paper trading platform.